Treating age-related multimorbidity: the drug discovery challenge

Christos Ermogenous; Charlotte Green; Thomas Jackson; Michael Ferguson; Janet M. Lord

doi:10.1016/j.drudis.2020.06.016

Treating age-related multimorbidity: the drug discovery challenge

Christos Ermogenous, Charlotte Green, Thomas Jackson, Michael Ferguson, Janet M. Lord^*

^*Corresponding author for this work

Inflammation and Ageing

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

Abstract

Advanced age is the major risk factor for multimorbidity. Current clinical practice treats the individual age-related diseases, resulting in polypharmacy. Thus, targeting the biological processes that drive ageing could prevent both multimorbidity and polypharmacy.

Original language	English
Pages (from-to)	1403-1415
Number of pages	13
Journal	Drug Discovery Today
Volume	25
Issue number	8
DOIs	https://doi.org/10.1016/j.drudis.2020.06.016
Publication status	Published - Aug 2020

Bibliographical note

Funding Information:
C.E. and C.G. are funded by the UK SPINE Knowledge Exchange network . We thank Teresa O’Leary for her help in identifying geroscience-informed trials in the USA. This paper presents independent research supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social care.

Publisher Copyright:
© 2020 The Authors

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1016/j.drudis.2020.06.016

Cite this

@article{e96081863f2d4293a6c6468298ea2fc9,

title = "Treating age-related multimorbidity: the drug discovery challenge",

abstract = "Advanced age is the major risk factor for multimorbidity. Current clinical practice treats the individual age-related diseases, resulting in polypharmacy. Thus, targeting the biological processes that drive ageing could prevent both multimorbidity and polypharmacy.",

author = "Christos Ermogenous and Charlotte Green and Thomas Jackson and Michael Ferguson and Lord, {Janet M.}",

note = "Funding Information: C.E. and C.G. are funded by the UK SPINE Knowledge Exchange network . We thank Teresa O{\textquoteright}Leary for her help in identifying geroscience-informed trials in the USA. This paper presents independent research supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social care. Publisher Copyright: {\textcopyright} 2020 The Authors Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = aug,

doi = "10.1016/j.drudis.2020.06.016",

language = "English",

volume = "25",

pages = "1403--1415",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Treating age-related multimorbidity

T2 - the drug discovery challenge

AU - Ermogenous, Christos

AU - Green, Charlotte

AU - Jackson, Thomas

AU - Ferguson, Michael

AU - Lord, Janet M.

N1 - Funding Information: C.E. and C.G. are funded by the UK SPINE Knowledge Exchange network . We thank Teresa O’Leary for her help in identifying geroscience-informed trials in the USA. This paper presents independent research supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social care. Publisher Copyright: © 2020 The Authors Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/8

Y1 - 2020/8

N2 - Advanced age is the major risk factor for multimorbidity. Current clinical practice treats the individual age-related diseases, resulting in polypharmacy. Thus, targeting the biological processes that drive ageing could prevent both multimorbidity and polypharmacy.

AB - Advanced age is the major risk factor for multimorbidity. Current clinical practice treats the individual age-related diseases, resulting in polypharmacy. Thus, targeting the biological processes that drive ageing could prevent both multimorbidity and polypharmacy.

UR - http://www.scopus.com/inward/record.url?scp=85087341241&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2020.06.016

DO - 10.1016/j.drudis.2020.06.016

M3 - Review article

C2 - 32574698

AN - SCOPUS:85087341241

SN - 1359-6446

VL - 25

SP - 1403

EP - 1415

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 8

ER -

Treating age-related multimorbidity: the drug discovery challenge

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this